Subtopic Deep Dive
Prostate Cancer Genomic Subtypes
Research Guide
What is Prostate Cancer Genomic Subtypes?
Prostate Cancer Genomic Subtypes classify tumors based on somatic mutations, copy number alterations, and gene fusions like TMPRSS2-ERG for prognostic and therapeutic stratification.
Researchers integrate genomic data with transcriptomics to reveal tumor heterogeneity and evolutionary dynamics (Abida et al., 2019; Quigley et al., 2018). TMPRSS2-ERG fusion duplication identifies fatal cases (Attard et al., 2007, 437 citations). Over 10 key papers since 2006 detail subtypes' clinical correlates, with Abida et al. (2019) at 1332 citations.
Why It Matters
Genomic subtypes predict aggressiveness and guide targeted therapies in precision oncology (Abida et al., 2019; Armenia et al., 2018). Quigley et al. (2018, 721 citations) identified structural variations in metastatic cases linked to outcomes. Wang et al. (2018) highlighted drivers for incurable advanced disease, enabling subtype-specific interventions like AR inhibitors (Watson et al., 2015).
Key Research Challenges
Tumor Heterogeneity Mapping
Intratumor genomic diversity complicates subtype classification (Quigley et al., 2018). Abida et al. (2019) showed heterogeneity impacts clinical outcomes in metastatic prostate cancer. Integrating multi-omics data remains challenging for accurate stratification.
Long Tail Driver Identification
Rare oncogenic drivers form a 'long tail' beyond common mutations (Armenia et al., 2018, 846 citations). Comprehensive profiling reveals low-frequency alterations affecting therapy response. Cataloging these for precision medicine requires large cohorts.
Resistance Mechanism Profiling
AR inhibitor resistance emerges via subtype-specific genomic changes (Watson et al., 2015, 1483 citations). Evolutionary dynamics in advanced disease evade treatments (Wang et al., 2018). Linking subtypes to resistance predicts therapeutic failure.
Essential Papers
Epidemiology of Prostate Cancer
Prashanth Rawla · 2019 · World Journal of Oncology · 2.6K citations
Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. Prostate cancer may be asymptomatic at the early stage and often has an indo...
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong et al. · 2019 · Journal of the National Comprehensive Cancer Network · 1.5K citations
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advance...
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Dong Gao, Ian Vela, Andrea Sboner et al. · 2014 · Cell · 1.5K citations
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson, Vivek Arora, Charles L. Sawyers · 2015 · Nature reviews. Cancer · 1.5K citations
Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida, Joanna Cyrta, Glenn Heller et al. · 2019 · Proceedings of the National Academy of Sciences · 1.3K citations
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity ...
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
Ryan Phillips, William Y. Shi, Matthew P. Deek et al. · 2020 · JAMA Oncology · 1.1K citations
ClinicalTrials.gov Identifier: NCT02680587.
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Chris Parker, Elena Castro, Karim Fizazi et al. · 2020 · Annals of Oncology · 892 citations
Reading Guide
Foundational Papers
Start with Attard et al. (2007) for TMPRSS2-ERG fusion in fatal cases, then Gao et al. (2014, 1519 citations) for organoid models of advanced subtypes.
Recent Advances
Study Abida et al. (2019) for outcome correlates and Quigley et al. (2018) for metastatic hallmarks.
Core Methods
Whole-genome profiling, mutation clustering, fusion detection, and multi-omics integration (Armenia et al., 2018; Abida et al., 2019).
How PapersFlow Helps You Research Prostate Cancer Genomic Subtypes
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map TMPRSS2-ERG literature from Attard et al. (2007), then findSimilarPapers uncovers Abida et al. (2019) on outcome correlates. exaSearch queries 'prostate cancer genomic subtypes structural variation' to retrieve Quigley et al. (2018).
Analyze & Verify
Analysis Agent applies readPaperContent to parse Abida et al. (2019) genomic data, verifyResponse with CoVe checks subtype-outcome claims, and runPythonAnalysis performs survival statistics on extracted mutations using pandas. GRADE grading scores evidence strength for prognostic subtypes.
Synthesize & Write
Synthesis Agent detects gaps in long-tail drivers from Armenia et al. (2018), flags contradictions in resistance papers. Writing Agent uses latexEditText for subtype review drafts, latexSyncCitations integrates 10+ papers, latexCompile generates polished manuscripts, and exportMermaid visualizes subtype evolution diagrams.
Use Cases
"Analyze survival data by genomic subtype in metastatic prostate cancer from recent papers."
Research Agent → searchPapers('genomic subtypes metastatic prostate') → Analysis Agent → readPaperContent(Abida 2019) → runPythonAnalysis(pandas survival curves by mutation subtype) → matplotlib plot of subtype-specific outcomes.
"Draft LaTeX review on TMPRSS2-ERG fusion subtypes and prognosis."
Synthesis Agent → gap detection(Attard 2007 + Armenia 2018) → Writing Agent → latexEditText(structured review) → latexSyncCitations(10 papers) → latexCompile(PDF with subtype tables).
"Find code for prostate cancer genomic subtype analysis from papers."
Research Agent → searchPapers('prostate genomic subtypes') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(python scripts for mutation clustering from Quigley-like data).
Automated Workflows
Deep Research workflow conducts systematic review of 50+ prostate subtype papers, chaining searchPapers → citationGraph → GRADE reports on Abida (2019) hallmarks. DeepScan applies 7-step analysis with CoVe checkpoints to verify Quigley et al. (2018) structural variations. Theorizer generates hypotheses on subtype evolution from Wang et al. (2018) drivers.
Frequently Asked Questions
What defines Prostate Cancer Genomic Subtypes?
Classification uses somatic mutations, copy number alterations, and fusions like TMPRSS2-ERG for prognosis (Attard et al., 2007).
What methods identify key subtypes?
Whole-genome sequencing reveals hallmarks like structural variations (Quigley et al., 2018) and long-tail drivers (Armenia et al., 2018).
What are key papers on subtypes?
Abida et al. (2019, 1332 citations) links genomics to outcomes; Attard et al. (2007) on TMPRSS2-ERG fatality.
What open problems exist?
Mapping intratumor heterogeneity and rare drivers for therapy resistance (Watson et al., 2015; Quigley et al., 2018).
Research Prostate Cancer Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Prostate Cancer Genomic Subtypes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.